By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.

OK

By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.

Pharmaceuticals

US agency approves cure for Sickle Cell Disease Leadership, Nigeria16:17CRISPR/Gene Editing FDA Business (US)

U.S. FDA approves two gene therapies for sickle cell disease CTV News Edmonton12:11CRISPR/Gene Editing FDA Business (US)

US approves CRISPR gene-editing to treat sickle cell disease Deutsche Welle14:55CRISPR/Gene Editing FDA

FDA approves two gene therapies for sickle cell, bringing hope to thousands with the disease WHDH-TV, Massachusetts14:11CRISPR/Gene Editing FDA

AbbVie buys Cerevel Therapeutics for $8.7B, Bolstering neuroscience portfolio Investopedia15:29AbbVie Biotech Cerevel Therapeutics

AbbVie to acquire Cerevel Therapeutics for $8.7 Billion European Pharmaceutical Manufacturer05:48AbbVie Biotech Cerevel Therapeutics

New sickle cell Drug awaiting FDA approval met with mixed emotions Black Enterprise10:03CRISPR/Gene Editing FDA

FDA approves two sickle cell therapies, including the first CRISPR medicine The Guam Daily Post09:15CRISPR/Gene Editing FDA

Merck-Eisai uterine cancer drug combination fails first-line treatment study Proactive Investors (US)09:37Keytruda Merck & Co Eisai

MSD’s Keytruda and Eisai’s Lenvima fail in Phase III uterine cancer trial Pharmaceutical Technology09:34Keytruda Merck & Co Eisai

The White House is threatening the patents of high-priced drugs developed with taxpayer dollars Orange County Register20:12White House Joe Biden Politics

Biden admin threatens to seize taxpayer-funded drug patents if pharmaceutical companies set prices too high The Blaze14:40White House Joe Biden Politics

Reno Omokri tackles Peter Obi as P&G moves to leave Nigeria following GSK’s exit Legit NG13:47GSK Peter Obi Nigeria

Peter Obi laments the exit of corporate giants P&G, GSK, others from Nigeria Report Afrique08:59GSK Peter Obi Nigeria

Assessing clinical trial efficacy vs real-World effectiveness in the treatment of multiple myeloma Pharmacy Times02:42Cancer Treatment Blood Cancer Canada

Merck's (MRK) Keytruda-Lynparza combo fails lung cancer study Zacks11:04Merck & Co Lung Cancer Cancer

Merck to discontinue Phase III lung cancer trial due to futility Clinical Trials Arena05:40Merck & Co Lung Cancer Cancer

Cambridge researchers redesign future mRNA therapeutics PharmaTimes06:31mRNA Coronavirus Vaccine Moderna Vaccine

Why are people talking about a redesign of the COVID-19 vaccines? IFLScience08:03mRNA Coronavirus Vaccine Moderna Vaccine

Latest News

In the last hour

Roche partner touts early allogeneic CAR-T data at ASH, but durability remains key question ENDPOINTS12:08

Derry mum in last ditch plea over cystic fibrosis medicines deemed 'too expensive' Belfast Live11:53

In the last 4 hours

New Sickle Cell Drug Awaiting FDA Approval Met With Mixed Emotions Black Enterprise10:03

Yoga-based interventions might improve anxiety and depression symptoms PsyPost09:03

AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024? The Motley Fool08:53

In the last 6 hours

Cipla unit recalls one lot of medication in US due to seal integrity issue The Times of India08:47

FDA Approves bluebird bio's Lovo-Cel Gene Therapy for Sickle Cell Disease American Journal of Managed Care08:35

Weight loss injections and suicide: Investigating the connection Jerusalem Post08:26

Is Now the Right Time to Buy AstraZeneca Stock? The Motley Fool07:21

Cencora's Brian Biehn Forecasts Big Changes for the US Biosimilar Space Center for Biosimilars07:15

3 Unstoppable Stocks to Buy Right Now The Motley Fool07:01

In the last 8 hours

AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? The Motley Fool05:59

Anti-aging drug for dogs from San Francisco firm moves closer to gaining FDA approval Fox News05:13

Earlier today

Turn Gaza border area into model of sustainable development, green organization says The Times of Israel03:27

Assessing Clinical Trial Efficacy Vs Real-World Effectiveness in the Treatment of Multiple Myeloma Pharmacy Times02:42

Week In Review: Abbisko Sells China Rights For CSF-1R Inhibitor To Merck In $605M Deal Seeking Alpha02:24

Nigerians in dire situation as pharmaceutical sector grapples with crisis over spiraling drug… Politics Nigeria01:26

‘Transformative’ sickle cell disease treatment closer to approval Nursing Times01:08

USFDA pulls up Intas Pharma for manufacturing lapses at Ahmedabad plant The Times of India00:35

Yesterday

AstraZeneca turns to AI for cancer antibody research CoinGeek23:03 9-Dec-23

Bluebird gene therapy, now approved for sickle cell, shows durable benefit in study update BioPharma Dive21:14 9-Dec-23

ASH23: CAR-T for autoimmune disease, real-world questions and sickle cell’s social media… BioPharma Dive20:33 9-Dec-23

Arcellx, Kite aim to keep chipping away at Carvykti advantage with new multiple myeloma data at ASH ENDPOINTS20:24 9-Dec-23

ASH: Pfizer, swimming in crowded waters, eyes wide impact for sickle cell, hemophilia assets FierceBiotech19:04 9-Dec-23

Union chemicals and fertilisers ministry says 303 of 504 central drug inspector posts vacant The Telegraph, Calcutta18:39 9-Dec-23

STAT Plus: Historic approval of sickle cell gene therapies met with cautious optimism by… STAT18:22 9-Dec-23

This startup is solving the biggest problem to creating drugs that work Freethink18:14 9-Dec-23

BeiGene builds out long-term case for Brukinsa in CLL, despite an overall survival miss: #ASH23 ENDPOINTS17:52 9-Dec-23

Biotech company seeks OK for major building addition Eden Prairie Local News17:00 9-Dec-23

US Agency Approves Cure For Sickle Cell Disease Leadership, Nigeria16:17 9-Dec-23

2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond The Motley Fool13:54 9-Dec-23

Masks are still being worn by some individuals—but not for health reasons The Times of India13:44 9-Dec-23

STAT Plus: Was CAR-T therapy a bystander or driver of lymphoma? Researchers examine first… STAT12:36 9-Dec-23

Health Equity and Access Weekly Roundup: December 9, 2023 American Journal of Managed Care12:13 9-Dec-23

Hawaiian acquired by Alaska Air, AbbVie boasters portfolio: 4 big deal... Investing.com11:09 9-Dec-23

Total wash elimination for solid phase peptide synthesis Nature.com10:20 9-Dec-23

Forget the "Magnificent Seven": Buy This Stock Instead The Motley Fool10:10 9-Dec-23

Offices as physical workplaces are likely to change significantly Echo Live09:36 9-Dec-23

Study shows challenges in long-term use of anti-obesity drugs Knowridge Science Report09:26 9-Dec-23

FDA approves two sickle cell therapies, including the first CRISPR medicine The Guam Daily Post09:15 9-Dec-23

12 Companies That Had IPOs in 1992: Best and Worst Performers 24/7 Wall St.08:54 9-Dec-23

HHS Publishes Roadmap of New Strategy for Cybersecurity in the Healthcare Sector Privacy Law Blog08:53 9-Dec-23

Departure of GSK, P&G, others to force 20,000 Nigerians out of jobs Legit NG08:44 9-Dec-23

'It's Transformed My Life': FDA Approves First Gene-Editing Treatment for Illness KQED08:41 9-Dec-23

US FDA approves $2.2m cure for sickle cell Graphic Online08:27 9-Dec-23

Could Sarepta Therapeutics Stock Help You Become a Millionaire? The Motley Fool07:08 9-Dec-23

Who is Siddharth Mittal: The CEO of Biocon, founded by Kiran Mazumdar Shaw; know about his career, education, and net… The Financial Express07:02 9-Dec-23

Eli Lilly granted planning for Dunderrow expansion Echo Live06:10 9-Dec-23

AbbVie’s $8.7B neuro gambit; Landmark sickle cell approvals; Roche buys a GLP-1 company; Endpoints 100 biotech survey;… ENDPOINTS06:09 9-Dec-23

Better Dividend Stock: AbbVie vs. Medical Properties Trust The Motley Fool05:16 9-Dec-23

Colorado blames Biden team and drugmakers for delaying Canadian imports The Colorado Sun04:23 9-Dec-23

FDA Inspections of Foreign Drug Manufacturers Haven't Bounced Back After Pandemic Medpage Today01:27 9-Dec-23

Vertex/CRISPR Nab First-Ever Gene Editing FDA Nod, Overshadow Bluebird’s Same-Day Win Scrip Pharma Intelligence00:50 9-Dec-23

In the last 7 days

JOINT FACT SHEET: Launching the U.S.-ROK Next Generation Critical and Emerging Technologies Dialogue The White House (Press Release)22:16 8-Dec-23

Did You Spot These Biotech High-Flyers In Advance? RTT News21:31 8-Dec-23

Why Cassava Sciences Stock Soared Today The Motley Fool19:36 8-Dec-23

Delisting: Shareholders approve N17.42 for GSK buyback The Punch18:58 8-Dec-23

Moderna and Pfizer COVID-19 vaccines authorized for sale in Mexico Mexico News Daily18:41 8-Dec-23

Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun BioSpace18:30 8-Dec-23

Setfirst Limited and SmithKline Beecham forego N2 Billion in favor of GSK Nigeria Shareholders Nairametrics17:41 8-Dec-23

Some Covid Vaccines Produce ‘Unintended Immune Response’ in Recipients: Study The Epoch Times17:18 8-Dec-23

Vertex and CRISPR Therapeutics gain FDA approval for CASGEVY - World’s first sickle cell treatment using CRISPR gene… NotebookCheck.net17:10 8-Dec-23

Colorado blames Biden administration, drugmakers for delaying Canadian imports Denver Post, Colorado17:04 8-Dec-23

Novo Nordisk Must Face Bulk Of Woman's Ozempic Injury Suit Law36017:03 8-Dec-23

FDA Approves First CRISPR Gene Editing Treatment for Sickle Cell Disease Scientific American16:41 8-Dec-23

STAT Plus: Vertex gets a win as Colorado board leaves cystic fibrosis drug off a list of… STAT16:33 8-Dec-23

STAT Plus: Tough road ahead for Bluebird Bio despite FDA approval for sickle cell therapy STAT16:07 8-Dec-23

Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2023) JD Supra16:01 8-Dec-23

Maker of $32,000 lead poisoning antidote pledges to create assistance program to help uninsured … CNN16:01 8-Dec-23

Merck (MRK) Shares Cross 3% Yield Mark Nasdaq15:54 8-Dec-23

J&J Hit With Suit Over Stelara Exclusivity Law36015:52 8-Dec-23

Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment MarketWatch15:44 8-Dec-23

1st gene therapies for sickle cell cleared by FDA, including CRISPR treatment Live Science15:42 8-Dec-23

STAT Plus: Medicare’s advisory committee isn’t sold on big pay raises for doctors STAT15:36 8-Dec-23

AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio Investopedia15:29 8-Dec-23

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia… BioSpace15:27 8-Dec-23

Widely used epilepsy drugs tied to rare, deadly side effect, FDA warns Live Science15:21 8-Dec-23

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma BioSpace15:17 8-Dec-23

Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of… BioSpace15:17 8-Dec-23

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease BioSpace15:17 8-Dec-23

Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With… BioSpace15:17 8-Dec-23

CRISPR-based gene editing therapy approved by the FDA for the first time Engadget15:14 8-Dec-23

Deal Watch: Vanda Buys US, Canadian Rights To J&J’s Ponvory Scrip Pharma Intelligence15:10 8-Dec-23

Medical Device Legal News with Sam Bernstein: Episode 18 JD Supra15:10 8-Dec-23

In brief: Novartis welcomes "significant milestone" for Kisqali London South East15:10 8-Dec-23

Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone… BioSpace15:07 8-Dec-23

bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with… BioSpace15:07 8-Dec-23

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of… BioSpace15:07 8-Dec-23

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive… BioSpace15:07 8-Dec-23

Boston Medical Center to Offer First FDA-Approved Gene Therapy Treatment Program for Sickle Cell Disease BioSpace15:07 8-Dec-23

Gene Therapy: A Promising Medical Frontier Hindered by Regulatory Roadblocks The Independent Institute (Weblog)15:05 8-Dec-23

Bluebird sinks on pricing plans, lack of priority review voucher for sickle cell gene therapy ENDPOINTS15:05 8-Dec-23

AbbVie teams with Parkinson’s disease foundation for 'Flipping the Switch' effort ENDPOINTS15:05 8-Dec-23

Patients expected Profemur artificial hips to last. Then they snapped in half Twin Cities Pioneer Press15:02 8-Dec-23

US approves CRISPR gene-editing to treat sickle cell disease Deutsche Welle14:55 8-Dec-23

New research points to potential link between GLP-1s and lowered risk of colorectal cancer ENDPOINTS14:55 8-Dec-23

eBook: Strengthening Europe’s Cell and Gene Therapy Sector — Safeguarding the Medicines of the… BioProcess Insider14:44 8-Dec-23

Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right… Nature.com14:43 8-Dec-23

UVA breaks ground on $350M biotechnology institute NBC 2914:42 8-Dec-23

FDA clears two sickle-cell gene therapies, including CRISPR ... pharmaphorum14:40 8-Dec-23

From Bacteria to Bedside: The Arrival of CRISPR Medicine Andreessen Horowitz14:38 8-Dec-23

FDA approves the first gene-editing treatment in the US Popular Science14:31 8-Dec-23

U.S. approves two ‘breakthrough’ gene therapies for sickle cell treatment Peoples Gazette14:27 8-Dec-23

Validea Detailed Fundamental Analysis - NVO Nasdaq14:22 8-Dec-23

Et Impact: Dcgi asks pharma cos to adhere to production quality standards The Times of India14:19 8-Dec-23

Pfizer mRNA jab leaves 1 in 3 recipients with 'unintended immune response': Cambridge study The Blaze14:13 8-Dec-23

GSK's Augmentin is India's no.1 drug brand The Times of India14:13 8-Dec-23

Workshop on AI for pharma & biotec The Hindu14:11 8-Dec-23

FDA approves two gene therapies for sickle cell, bringing hope to thousands with the disease WHDH-TV, Massachusetts14:11 8-Dec-23

Regeneron's linvoseltamab shows promise in multiple myeloma trial Investing.com14:10 8-Dec-23

First CRISPR Sickle Cell Patient ‘Reborn’: FDA Approves Treatment Forbes14:07 8-Dec-23

FDA approves first use of CRISPR gene editing to treat sickle cell disease The Fresno Bee14:01 8-Dec-23

India’s alarming ‘fixed dose combination’ problem The Hindu13:51 8-Dec-23

6 crore hospital admissions costing Rs 77,298 cr authorised under Ab PM-Jay till Nov 30: Govt… The Times of India13:49 8-Dec-23

White House Fights to Lower Drug Prices TIME13:47 8-Dec-23

view more headlines

10 Dec 12:08

About our Pharmaceuticals news

NewsNow aims to be the world's most accurate and comprehensive pharmaceutical news aggregator, bringing you the latest headlines from the best pharma sites and other key national and regional news sources. Every story from every site is brought to you automatically and continuously 24/7, within around 10 minutes of publication.

Publication filters

Notifications

Unsubscribe from Breaking News

Sorry, no headlines or news topics were found. Please try different keywords.